Pfizer and Moderna have collectively generated approximately $171 billion in revenue from their COVID-19 products, including vaccines and treatments like Paxlovid, from 2020 through the third quarter of 2025. This substantial revenue figure is based on the companies' financial reports and earnings data, highlighting the significant financial impact of their pandemic-related products over the past five years.